Webster Equity Partners to acquire Lifecore for up to $663.7m

Lifecore Biomedical, Inc., a biomedical company listed on the NASDAQ, has agreed to be acquired by Webster Equity Partners. The deal is valued at up to $663.7 million, contingent upon meeting certain performance milestones. For $6.28 per share in cash, plus one non-tradable contingent value right (CVR) per share, Webster Equity Partners will acquire all outstanding Lifecore common stock at closing.

This represents a 49.5% premium to Lifecore's closing price on the last trading day prior to the merger agreement's signing. The initial cash payment would be approximately $50.2 million per share of common stock, equivalent to the Conversion Amount as of June 30, 2026. If all performance milestones are achieved, stockholders may receive up to $9.67 per common equivalent in combined cash and CVR payments.

The transaction is expected to close at the end of Q4 2026, contingent on stockholder approval, regulatory approvals, and other closing conditions. Lifecore's common stock will be delisted from the Nasdaq after the merger.